Skip to main content
Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Enter a zip code
Or
Select a campus/region
(904) 244-0411

A study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease

  • Status
    Accepting Candidates
  • Age
    18 Years - 100 Years
  • Sexes
    All
  • Healthy Volunteers
I'm interested
Share this study
Facebook
Twitter
LinkedIn

Description

This study is a Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study. The purpose of this study is to learn about the effects of epetraborole in patients with refractory MAC, including to assess the efficacy for treating refractory MAC, to see how safe epetraborole is for patients with refractory MAC, to understand the amount of epetraborole in the body and to assess how patients feel while taking the study medicine. The study will also compare the effects of, epetraborole plus optimized background regimen (OBR), to placebo plus OBR to find out which is better for treating MAC.

Details

Protocol number EBO-301

Eligibility

Inclusion criteria: Patients with a diagnosis of treatment-refractory Mac lung disease, defined as respiratory specimen positive for Mac despite receiving a combination regimen of =2 antimycobacterial agents administered for =6 months.

Exclusion criteria:

Patients with a presence of any suspected or confirmed disease or condition that may confound the assessment of symptom-based clinical response, including, but not limited to, the following: • Radiographic presence of any cavity >5.0 cm internal diameter • Cystic fibrosis or other inherited disorders of airway ciliary dysfunction • Active allergic bronchopulmonary mycosis • Anticipated or planned lung surgery for treatment of MAC lung disease • Disseminated MAC infection, or other known or suspected non-pulmonary source of infection (eg, infective endocarditis, osteomyelitis, meningitis, or urinary tract infection) requiring non-study antimicrobial therapy • Concomitant pulmonary infection requiring antimicrobial therapy •Patients with active pulmonary malignancy

Lead researcher

  • Mehdi S Mirsaeidi, MD, MPH
    Pulmonologist, Critical Care Medicine Physician
    Languages: Persian

Participate in a study

Here are some general steps to consider when participating in a research study:

  1. Step
    1

    Contact the research team

    Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.

    Primary contact

  2. Step
    2

    Get screened to confirm eligibility

    You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.

  3. Step
    3

    Provide your consent to participate

    If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.

  4. Step
    4

    Participate

    If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.